Gritgen Therapeutics

Executive Summary

Gritgen Therapeutics is a Shanghai-based biotechnology company specializing in next-generation AAV-based gene therapies. Founded in 2019, the company has developed proprietary capsid platforms and efficient promoter/enhancer systems to improve delivery and expression of therapeutic genes. Their lead candidate, GS1191, targets hemophilia A and has entered Phase I clinical trials in China. The company's pipeline also explores applications in other rare and common genetic diseases, leveraging its innovative AAV engineering capabilities. With a strong focus on addressing high unmet needs in hematology and rare diseases, Gritgen positions itself as a key player in China's growing gene therapy landscape. Despite its early stage, the company's differentiated technology and initial clinical progress warrant attention.

Upcoming Catalysts (preview)

• H2 2026Phase I data readout for GS1191 in hemophilia A40% success
• 2027IND filing for a second pipeline candidate (e.g., in another rare disease)50% success
• TBDPotential strategic partnership or licensing deal for capsid platform30% success